Click Here to return To Results

 

Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine NEJM 381:142-149, Lipton, R.B.,et al, 2019 See this aricle in Pubmed Article Abstract Treatment of a migraine attack with the oral calcitonin gene-related peptide receptor antagonist rimegepant resulted in a higher percentage of patients who were free of pain and free from their most bothersome symptom than placebo.

Related Tags

(click to filter results - removes previous filter) calcitonin gene-related peptide receptor blocker efficacy migraine migraine,treatment of rimegepant safety treatment of neurologic disorder

Click Here to return To Results